Vitreous Levels of Cysteine-rich 61 in Patients With Proliferative Diabetic Retinopathy

• Status: Completed
• Trial end date: 2006-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To determine the vitreous levels of fractalkine, cysteine-rich 61 (Cyr61), and VEGF in patients with PDR. Verifying that it is greater to that found in non-diabetic patients with different non-angiogenetic diseases.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Taiwan University Hospital
• Treatments: Bevacizumab

Criteria

Inclusion Criteria:

• Age ≥ 18 years

• Patients with type 1 or type 2 diabetes mellitus

• Not eligible for any currently approved treatments or experimental protocols

• Patients with PDR who receiving vitreoretinal surgery.

Exclusion Criteria:

• A condition that would preclude a patient for participation in the study in opinion of investigator, e.g., unstable medical status including glycemic control and blood pressure

• Panretinal laser photocoagulation in the study eye

• Previous treatment with intravitreal or sub-Tenon triamcinolone

• History of submacular surgery or other surgical intervention for diabetic